Q Bio
Q Bio operates a Clinical Digital Twin Platform that combines whole-body MRI, 120+ biomarkers, 163-gene genetic screening, wearable data, and physician review into a single longitudinal health record, delivered directly at its Redwood City clinic and through enterprise health partners.
- Company typePrivate
- Founded2015
- HeadquartersRedwood City, United States
- Headcount101–250
- GTM typeB2B and B2C
- OfferingServices
What Q Bio does
Q Bio, founded in 2015 and headquartered in Redwood City, California, is a private health technology company building a Clinical Digital Twin Platform that integrates whole-body MRI, biomarker analysis, genetic screening, wearable data, and physician review into a single longitudinal health record. The core product is the Q Exam, a 75-minute in-clinic service priced at $3,495 per annual membership that captures non-contrast whole-body MRI imaging (9,500+ images across 10 sequences), 120+ blood and urine biomarkers, 163 clinically actionable genetic markers, vitals, and a 45-minute physician data review. The Q Bio Health Dashboard unifies these inputs into a longitudinal record organized across nine body systems, enabling year-over-year comparison for returning members. Constellation, the company's FDA 510(k)-cleared AI image-analysis software, performs automated organ and tissue segmentation from MRI scans and produces standardized measurements that make cross-visit comparison operationally viable.
Q Bio operates a dual go-to-market model. On the consumer side, individuals book the Q Exam directly at the Redwood City flagship clinic, which runs three appointment slots per day Monday through Friday. On the enterprise side, Q Bio partners with concierge medicine practices, executive health programs, longevity clinics, health systems, and employer member programs to deploy the Q Exam under the partner's brand, with Q Bio supplying the protocol, data infrastructure, and Dashboard layer. Enterprise deployments typically move from kickoff to live operation in approximately 4-6 months and are evaluated for international rollout on a partner-by-partner basis. The company does not accept insurance but the service qualifies for HSA/FSA reimbursement.
The company has raised approximately $91M in cumulative venture funding across rounds in 2016 ($7.5M), 2018 ($16.5M), 2020 ($40M), and 2024 ($27M), with investors including Andreessen Horowitz, Founders Fund, Khosla Ventures, Kaiser Permanente, and TELUS Global Ventures. Leadership combines Stanford, Harvard, MIT, UnitedHealth, Abbott, and Dexcom alumni. Q Bio holds no public listing and operates as Q Bio, Inc., a Delaware corporation.
Q Bio firmographics
Firmographics- Name
- Q Bio
- Legal name
- Q Bio, Inc.
- Website
- https://q.bio
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Q Bio operates a Clinical Digital Twin Platform that combines whole-body MRI, 120+ biomarkers, 163-gene genetic screening, wearable data, and physician review into a single longitudinal health record, delivered directly at its Redwood City clinic and through enterprise health partners.
- Ownership category
- akta.pro rank
Q Bio industry classification
Industry- Product category
- Preventive Health Diagnostics
- NAICS
- Medical Laboratories (621511), Diagnostic Imaging Centers (621512)
- SIC
- Services-Medical Laboratories (8071), Services-Offices & Clinics Of Doctors Of Medicine (8011)
- akta.pro primary industry
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
- akta.pro secondary industry
- Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
Keywords
Where Q Bio is headquartered
LocationHeadquarters
- HQ city
- Redwood City
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Q Bio business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Revenue model
- Annual Q Exam Membership: Individual consumers pay $3,495 USD annually for access to the Q Exam, which includes the 75-minute whole-body MRI, biomarkers (120+), genetics (163 genes), vitals, physician review, and 45-minute Data Review session. This is a recurring annual subscription model where members return for follow-up exams that compound in longitudinal value.
- Enterprise Partner Deployment: Q Bio provides its protocol, data infrastructure, and Q Bio Health Dashboard to enterprise health partners who deploy the Q Exam within their own branded clinical environments. Partners provide the clinical setting, physician relationship, and member base while Q Bio supplies the underlying platform. Commercial terms vary by partner type, scope, and geography.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Individual Annual Membership at Redwood City Clinic |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Q Bio product offering
Product offeringCore offering
Q Bio operates the Q Exam, a single 75-minute in-clinic comprehensive physical examination that captures non-contrast whole-body MRI (9,500+ images across 10 sequences), 120+ blood and urine biomarkers, 163-gene genetic screening, wearable data integration, and a 45-minute board-certified physician Data Review. Results are unified in the Q Bio Health Dashboard, a longitudinal clinical interface powered by the FDA 510(k)-cleared Constellation AI image-analysis software, enabling year-over-year comparison of every subsequent exam.
Product overview
Q Bio delivers a unified preventive health platform consisting of two integrated products: the Q Exam and the Q Bio Health Dashboard, powered by Constellation (FDA-cleared AI image-analysis software). The Q Exam is the in-clinic service capturing whole-body MRI, 120+ biomarkers, 163 genetic markers, wearable data, and physician review in a single 75-minute visit. The Q Bio Health Dashboard is the longitudinal product surface that unifies all captured inputs into a comparative clinical record, organized by nine body systems, accessible to both patients and clinicians. The Dashboard compounds in value with each subsequent exam, enabling year-over-year comparison of imaging, biomarker trends, and findings. The platform is available directly at Q Bio's Redwood City clinic and through enterprise partner deployments where Q Bio serves as the infrastructure layer beneath the partner's brand.
Differentiator
Problem solved
Functional benefit
Brands
- Q Exam: The comprehensive whole-body physical exam combining MRI, biomarkers, genetics, wearable data, and physician review.
- Q Bio Health Dashboard
- Constellation
Products and services
- Q Exam A comprehensive in-clinic physical examination combining whole-body MRI (non-contrast, 9,500+ images across 10 sequences), 120+ blood and urine biomarkers, genetic screening of 163 clinically actionable genes, wearable device and prior medical record integration, and a 45-minute physician Data Review. Designed to establish a quantitative longitudinal health baseline captured in a single 75-minute visit for individual members and enterprise partner programs.
- Q Bio Health Dashboard A longitudinal clinical interface that integrates imaging, biomarkers, genetics, wearable data, and physician-reviewed findings into a unified record organized by nine body systems. Delivered as both patient-facing and clinician-facing views, with year-over-year comparison capabilities, flagged out-of-range biomarkers, and shareable exports for the member's primary care team.
- Constellation Q Bio's FDA 510(k)-cleared image-analysis software for whole-body MRI processing. Uses AI/machine-learning methods to segment anatomical regions (lung, liver, brain, and other structures), quantify key measurements, and organize results for radiologist and physician review. Standardized measurements enable direct comparison across visits.
Quantifiable outcome
- 9,500+ images captured per whole-body MRI scan
- +3 more outcomes
Companies that use Q Bio
Customer profileNamed customers1 record
Segments7 records
Ideal customer profiles5 records
Q Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability4 records
Feature5 records
Q Bio partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- Stanford UniversitycoreMichael Snyder, PhD, Chair of Genetics and Professor of Genomics at Stanford University, serves as Scientific Advisor and Co-founder of Q Bio. He previously served as director of the Yale Center for Genomics and Proteomics. Academic partnership provides scientific expertise and research credibility for Q Bio's quantitative biology approach.
- Harvard UniversitycoreQ Bio's Chief Medical Officer & Co-founder is a former Harvard Medical School faculty member and board-certified radiologist. Garry Choy, MD/MBA, Co-founder, is also Harvard-affiliated. Harvard partnership provides medical leadership and clinical research credibility.
- Massachusetts General HospitalcoreClinical advisors with MGH affiliation provide medical expertise. MGH partnership contributes to Q Bio's clinical validation approach and reinforces the company's positioning within academic medical center circles.
- Massachusetts Institute of Technology (MIT)coreThomas Witzel, PhD, Chief Scientific Officer, has a key role in development of the Connectome MRI scanner and holds a PhD from Harvard-MIT Health Sciences & Technology. MIT affiliation contributes to Q Bio's MRI technology development.
Scale indicators2 records
Recent moves8 records
Expansion highlights6 records
Q Bio competitors and assessment
Company assessmentDirect peers
- Prenuvo: Prenuvo offers whole-body MRI screening combined with optional blood biomarkers as a direct-to-consumer preventive health service. It is the most direct competitor to Q Bio's Q Exam, with overlapping target customer (health-conscious affluent adults) and similar MRI-plus-biomarker value proposition, though without Q Bio's FDA-cleared AI platform layer.
- Ezra: Ezra provides whole-body MRI-based cancer and disease screening as a direct-to-consumer service using AI-assisted image analysis. It competes directly with Q Bio on MRI-based preventive screening for affluent consumers, with a similar AI-image-analysis value proposition though a narrower focus on oncology.
- Human Longevity Inc: Human Longevity Inc (HLI) was a pioneer in combining whole-body MRI, whole-genome sequencing, and advanced biomarker testing into a comprehensive health assessment. It is a direct peer in offering integrated imaging-plus-genomic-plus-biomarker preventive health to high-net-worth and executive consumers.
- Function Health: Function Health offers a comprehensive blood-based biomarker panel (100+ markers) via direct-to-consumer subscription with physician review and longitudinal tracking. It competes directly with Q Bio on the 'comprehensive preventive panel + physician review + longitudinal record' value proposition, though without the imaging component.
- InsideTracker: InsideTracker provides blood-based biomarker analysis with personalized recommendations and longitudinal tracking for health optimization and longevity. It overlaps with Q Bio on the biomarker-tracking and longevity consumer segment, with similar longitudinal dashboard UX though narrower scope than Q Bio's MRI-based offering.
- Forward Health: Forward Health operates membership-based preventive primary care clinics combining body scanning, blood testing, and AI-driven health insights. It is comparable to Q Bio as a tech-enabled preventive health membership model targeting affluent health-conscious consumers, with an owned-clinic distribution approach.
- Fountain Life: Fountain Life operates preventive health and longevity centers offering whole-body MRI, advanced biomarker panels, and genetic testing to affluent members. It is comparable to Q Bio as a premium integrated preventive health platform targeting the same longevity-focused, high-net-worth consumer segment.
Broad incumbents
- Tempus Labs: Tempus is a large precision medicine company applying AI to molecular and clinical data across oncology and beyond. While broader in scope and B2B-oriented, its AI-enabled diagnostics platform overlaps conceptually with Q Bio's Constellation AI image-analysis approach and longitudinal multimodal data positioning.
- Color Health: Color Health combines genetic testing with preventive health screening and virtual care delivery to employers, health systems, and consumers. It overlaps with Q Bio on the genetic-screening + preventive-health value proposition and shares the enterprise partner channel strategy with employers and health systems.
Emerging players
- Lunit: Lunit develops FDA-cleared AI medical imaging analysis software (notably for mammography and chest X-ray) sold to hospitals and radiology providers. It is comparable to Q Bio's Constellation as a regulatory-cleared AI image-analysis platform for clinical imaging, though Lunit focuses on single-modality clinical AI while Constellation targets whole-body MRI.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
Q Bio social profiles
Digital presenceQ Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Q Bio leadership team
Management profileNumber of profiles
Profiles6 records
Q Bio funding detail
Funding detailFunding overview
Funding rounds5 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Q Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Q Bio
What does Q Bio do?
Q Bio operates the Q Exam, a single 75-minute in-clinic comprehensive physical examination that captures non-contrast whole-body MRI (9,500+ images across 10 sequences), 120+ blood and urine biomarkers, 163-gene genetic screening, wearable data integration, and a 45-minute board-certified physician Data Review. Results are unified in the Q Bio Health Dashboard, a longitudinal clinical interface powered by the FDA 510(k)-cleared Constellation AI image-analysis software, enabling year-over-year comparison of every subsequent exam.
Is Q Bio a public or private company?
Q Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Q Bio founded?
Q Bio was founded in 2015. It employs 101 to 250 people.
Where is Q Bio based?
Q Bio is headquartered in Redwood City, United States, in the North America region.
How does Q Bio make money?
Two revenue lines are on record. Annual Q Exam Membership is the primary driver. The others are enterprise Partner Deployment.
Who are Q Bio's main competitors?
Direct peers on record are Prenuvo, Ezra, Human Longevity Inc, Function Health, InsideTracker, Forward Health and Fountain Life. Broad incumbents are Tempus Labs and Color Health. Lunit is listed as an emerging player.
Does Q Bio have an API?
No public API is recorded for Q Bio.
What industry is Q Bio in?
Q Bio's product category is Preventive Health Diagnostics. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HLAFAMAE, Molecular Diagnostics & Genomics Laboratories. Its NAICS code is 621511 and its SIC code is 8071.